264 related articles for article (PubMed ID: 31922558)
21. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
22. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
23. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
24. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis.
Zhan J; Yang S; Zhang W; Zhou D; Zhao D; Zhang Y; Wang W; Wei C
Future Oncol; 2023 Oct; 19(31):2123-2133. PubMed ID: 37882339
[No Abstract] [Full Text] [Related]
26. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
27. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
Colloca G; Venturino A
Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
[TBL] [Abstract][Full Text] [Related]
28. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
29. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.
Jin Y; Ren H; Yue Q; Wu W; Liu C; Guo Y; Zhao P
BMC Cancer; 2024 Feb; 24(1):258. PubMed ID: 38395854
[TBL] [Abstract][Full Text] [Related]
30. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
[TBL] [Abstract][Full Text] [Related]
31. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
32. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK
JCO Precis Oncol; 2024 Jan; 8():e2300296. PubMed ID: 38207226
[TBL] [Abstract][Full Text] [Related]
33. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
34. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
35. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
36. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
[TBL] [Abstract][Full Text] [Related]
37. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
38. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
[TBL] [Abstract][Full Text] [Related]
39. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
[TBL] [Abstract][Full Text] [Related]
40. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
